Register to chat with like-minded investors on our interactive forums.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Astrazeneca Plc | LSE:AZN | London | Ordinary Share | GB0009895292 | ORD SHS $0.25 |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 112.00 | 0.94% | 11,994.00 | 11,994.00 | 12,000.00 | 12,018.00 | 11,854.00 | 11,860.00 | 2,284,602 | 16:29:59 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| Pharmaceutical Preparations | 54.07B | 7.04B | 4.5370 | 26.44 | 184.24B |
From Mar 2020 to Mar 2025
LONDON--AstraZeneca PLC (AZN.LN) on Wednesday said it has increased its equity interest in U.S.-based biotechnology company Moderna Therapeutics with a $140 million investment.
The U.K.-listed pharmaceutical company now owns a 9% stake in Moderna after the transaction, which was made as part of Moderna's preferred-stock financing.
AstraZeneca previously acquired an equity stake in Moderna after a collaboration agreement, announced in March 2013, to develop medicines for cardiovascular, metabolic and renal diseases, as well as oncology. The companies also entered into a further collaboration agreement in January 2016 to develop and commercialize cancer medicines.
Shares of AstraZeneca at 1352 GMT were trading 0.6% lower at 5,147 pence.
Write to Tapan Panchal at tapan.panchal@wsj.com
(END) Dow Jones Newswires
August 10, 2016 10:40 ET (14:40 GMT)
Copyright (c) 2016 Dow Jones & Company, Inc.
1 Year Astrazeneca Chart |
1 Month Astrazeneca Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
